How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CR

NASDAQ:CRNX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

CR

Crinetics Pharmaceuticals IncNASDAQ CRNX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is CRNX undervalued compared to its fair value?

The fair value of CRNX stock is hidden USD. Relative to the market price of 52.66 USD Crinetics Pharmaceuticals Inc is hidden.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tum...[More about valuation]

Crinetics Pharmaceuticals Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

4.133 $B

Price:

52.66 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.93

FINANCIALS

Crinetics Pharmaceuticals financial for reporting period

Income Statement

0.0006 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.074 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.067 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0006 B 100%
-0.074 B -11489%
-0.067 B -10458%

Balance Sheet

0.98 B
0.87 B

Financial Position Analysis

Assets

0.98 B
Current Assets
0.92 B
Total non-current assets
0.061 B

Total current liabilities
0.052 B
Total non-current liabilities
0.051 B

Cash Flow Statement

-0.054 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.053 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Crinetics Pharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-43 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-980 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-37 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is CRNX attractive for investment based on fundamental analysis?

CRNX stock rating is hidden. Crinetics Pharmaceuticals is a hidden by Eyestock methodology.

Get CRNX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-11 892

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

13.933

Debt / Equity ratio:

ROE:

-43

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

CRNX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for CRNX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Crinetics Pharmaceuticals Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Crinetics Pharmaceuticals Inc dividends

CRNX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About CRNX stock

About the company Crinetics Pharmaceuticals Inc

Market cap $B

4.133

Dividend yield

Shares outstanding

53.9089 B

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 210 full-time employees. The company went IPO on 2018-07-18. The firm is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).

CRNX profile

  • Ticker

    CRNX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    18 July 2018

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    210

  • City

    San Diego

  • Address

    10222 Barnes Canyon Rd Bldg 2

  • Cusip

    22663K107